NasdaqGS:DOCUSoftware
DocuSign (DOCU) Faces ARR Doubts, Is The Upside Already Priced In?
Investor focus on DocuSign (DOCU) has intensified after the latest quarter highlighted underwhelming annual recurring revenue growth and a negative customer acquisition cost payback period, raising questions about demand quality and sales efficiency.
See our latest analysis for DocuSign.
That cautious tone around DocuSign’s annual recurring revenue and sales efficiency sits against a sharp 25.7% 30 day share price return and a 23.7% 90 day share price return, yet the stock’s year to date...